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Abstract
Background: Healing after acute myocardial infarction (AMI) is characterized by an intense inflammatory response and
increased Interleukin-1 (IL-1) tissue activity. Genetically engineered mice lacking the IL-1 receptor (IL-1R1-/-, not responsive
to IL-1) or the IL-1 receptor antagonist (IL-1Ra, enhanced response to IL-1) have an altered IL-1/IL-1Ra balance that we
hypothesize modulates infarct healing and cardiac remodeling after AMI.
Methods: IL-1R1-/- and IL-1Ra-/- male mice and their correspondent wild-types (WT) were subjected to permanent coronary
artery ligation or sham surgery. Infarct size (trichrome scar size), apoptotic cell death (TUNEL) and left ventricular (LV)
dimensions and function (echocardiography) were measured prior to and 7 days after surgery.
Results: When compared with the corresponding WT, IL-1R1-/- mice had significantly smaller infarcts (225%), less
cardiomyocyte apoptosis (250%), and reduced LV enlargement (LV end-diastolic diameter increase [LVEDD], 220%) and
dysfunction (LV ejection fraction [LVEF] decrease, 250%), whereas IL-1Ra-/- mice had significantly larger infarcts (+75%),
more apoptosis (5-fold increase), and more severe LV enlargement (LVEDD increase,+30%) and dysfunction (LVEF decrease,
+70%)(all P values ,0.05).
Conclusions: An imbalance in IL-1/IL-1Ra signaling at the IL-1R1 level modulates the severity of cardiac remodeling after
AMI in the mouse, with reduced IL-1R1 signaling providing protection and unopposed IL-1R1 signaling providing harm.
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encoding for IL-1Ra (IL-1Ra-/-mice) have enhanced response to
IL-1, are more susceptible to Listeria monocytogenis infections,
and may develop spontaneously occurring inflammatory arthritis
and arteritis [4–6]. However, no gross cardiac abnormalities have
been reported in these mice.
In many conditions, the balance between IL-1b and IL-1Ra at
the receptor level determines the inflammatory activity and
severity of the disease [3,7]. IL-1 is known to influence ischemia,
heart failure, and cardiac remodeling after acute myocardial
infarction in the mouse [8–10]. In order to demonstrate the pivotal
role of IL-1 signaling on cardiac remodeling after AMI, we studied
two independent strains of mice with genetic modifications that
alternatively enhanced IL-1 signaling (IL-1Ra deletion, IL-1Ra-/-)
or suppressed IL-1 signaling (IL-1R1-/-) in a model of severe
ischemic cardiomyopathy due to permanent coronary artery
ligation.

Introduction
Healing and cardiac remodeling after acute myocardial infarction
(AMI) are characterized by an intense inflammatory response within
the myocardium. Interleukin-1b (IL-1b) is a potent pro-inflammatory mediator with local and systemic effects mediated by the IL-1
type I receptor (IL-1R1), the only signaling membrane receptor for
IL-1b [1]. Genetically engineered mice lacking the gene encoding for
the IL-1 type I receptor (IL-1R1-/- mice) are not responsive to IL-1b
or IL-1a, but have an otherwise normal phenotype and remain
responsive to other pro-inflammatory stimuli such as lipopolysaccharide (LPS) and Tumour Necrosis Factor-a [1–2].
Interleukin-1 receptor antagonist is a natural occurring protein
that competitively inhibits IL-1b (and IL-1a) signalling, but fails to
recruit the IL-1 receptor associated protein and therefore does not
transduce signal [1–3]. Mice with genetic deletion of the gene
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(VisualSonics Inc., Toronto, Canada), equipped with a 30 MHz
probe, as previously described [8]. Briefly, the heart was imaged in
the short-axis view of the LV. The M-mode cursor was positioned
perpendicular to the anterior wall in order to measure left
ventricular end-diastolic and end-systolic diameters (LVEDD and
LVESD, respectively) at the level of the papillary muscles below
the mitral valve tip. LV ejection fraction (LVEF) and mass were
calculated. The investigator performing and reading the echocardiogram was blinded to the mouse genotype and surgical
procedure performed.

Methods
Experimental design
IL-1R1-/- male mice (strain B6.129S1-Il1r1tm1Roml/J) and the
corresponding wild-type adult male mice (strain B6.129SF2J) were
purchased from Jackson Laboratory (Maine, USA)[11].
IL-1Ra-/- male mice (strain B6.129S-IL-1RNtm1Dih/J) were
also purchased from Jackson Laboratory [12] and wild-type adult
male mice (strain C56BL/6J) were used as recommended by the
supplier in consideration of the backcrossing of the B6-129
generated mouse into the C56BL line [12].
All animal experiments were conducted under the guidelines on
humane use and care of laboratory animals for biomedical
research published by National Institutes of Health (No. 85-23,
revised 1996). The study was approved by the Institutional Animal
Care and Utilization Committee (IACUCU) of the Virginia
Commonwealth University (AM20114). Mice were received at
variable ages. Upon their arrival, all animals were allowed to
readjust to the housing environment for at least 7 days before any
experiment, with freely accessible standard rodent food and water.
All mice were between 14 and 16 weeks at time of surgery.
AMI by permanent left coronary artery ligation was induced in
4 groups of mice (IL-1R1-/- and B6.129 WT mice; IL-1Ra-/- and
C57Bl WT mice)(N = 10–12 per group), while 4 additional groups
of mice (N = 5) underwent a sham operation including every step
except the coronary artery ligation. The mice were then allowed to
recover for 7 days.

Statistical analysis
Data are presented as mean and standard error of the mean.
Comparisons between the genetically modified mice (IL-1R1-/- or
IL-1Ra-/-) and the corresponding WT at a single time point was
performed using the Student T test for unpaired data. In order to
compare changes over time between 2 groups, ANOVA for
repeated measures was using analyzing the effect of time_
x_interaction. SPSS 16.0 package was used. Two-tail significance
was set at 0.05.
Direct comparison between the IL-1R1-/- and IL-1Ra-/- mice
was not possible considering that 2 strains had different genetic
background (B6.129 and C57Bl, respectively), therefore in order to
visually compare the IL-1R1-/- and IL-1Ra-/- mice, the values of
LVEDD, LVESD, LVEF, infarct size and apoptosis was
normalized to the corresponding WT, and expressed as% of WT.

Results

Surgical procedure

Cardiac morphology

The animals under anesthesia (pentobarbital 50–70 mg/Kg)
were orally intubated, and then underwent opening of the chest
and ligation of the left coronary artery (or sham surgery, in which
the needle was passed around the artery but it was not ligated), as
previously described [8].

IL-1R1-/- mice had significantly smaller body weight but
similar LV mass reflecting a significantly increased LV mass to
body weight ratio (Figure 1). IL-1Ra-/- mice also had significantly
smaller body weight, but similar LV mass and similar LV mass to
body weight ratio (Figure 1).

Histology
Survival after surgery

For immunofixation, animals were sacrificed at 7 days and the
heart was then mounted on a Langendorff apparatus. The
coronary arteries were perfused with 10% formalin and subsequently the whole heart was submersed in the same solution. After
fixation, the mid-ventricular section of each heart was cut (approx.
3 mm thickness) and then the samples were dehydrated and
included in paraffin.
The infarct scar size was measured as scar area in sections
stained with Masson’s trichrome (Sigma-Aldrich, St Louis, Mo) by
computer morphometry using a BIOQUANT imaging software
and expressed as a percentage of the whole left ventricle midventricular section.
Nuclear DNA fragmentation (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling–ApopTag, Chemicon)
was used as a marker for apoptosis. Only cardiomyocytes (cardiac
actin+) expressing TUNEL staining in the nucleus were counted in
the peri-infarct area, defined as the zone bordering the infarct
where viable myocardium was prevalent and reparative fibrosis
was only marginal, and in the remote unaffected myocardium.
The apoptotic rate (AR) is expressed as the number of apoptotic
cardiomyocytes on all cardiomyocytes per field, analysing 5 of
more fields covering the entire infarct and border zones in the
mid-ventricular section. The pathologist performing the count was
unaware of the mouse genotype or surgical procedure performed.

Two of 12 (17%) of IL-1R1-/- mice and 5 of 14 (36%) of the
corresponding WT mice died after AMI surgery. Eight of 15 (54%)
IL-1Ra-/- mice died after coronary artery ligation surgery
compared to 4 of 12 (33%) of the corresponding WT mice. Free
wall cardiac rupture was found in 2 IL-1Ra-/- mice (13%), none of
the IL-1R1-/- mice, and none of the WT mice. None of the sham
operated animals died. None of the differences reached the
statistical significance set at a P of 0.050.

Infarct scar size
Infarct scar size was measured 7 days after AMI surgery.
Figures 2 and 3 show representative images from the AMI groups
for the IL-1R1-/- and IL-1Ra-/-, respectively. When compared
with the corresponding WT mice, IL-1R1-/- mice had a
significantly smaller infarct size, whereas IL-1Ra-/- had a
significantly larger infarct size. Sham operated mice had no
measurable infarct (data not shown).

Cardiomyocyte apoptosis
Cardiomyocyte apoptosis was significantly greater in the periinfarct myocardium versus the remote myocardium and versus the
anterior wall in sham operated animals in all 4 groups. When
compared with the corresponding WT mice, IL-1R1-/- mice had
significantly less cardiomyocyte apoptosis in the peri-infarct
myocardium (Figure 2), whereas IL-1Ra-/- mice had significantly
more cardiomyocyte apoptosis both in the peri-infarct and remote
myocardium (Figure 3).

Echocardiography
Transthoracic echocardiography was performed before surgery
and 7 days later, using the Vevo770TM imaging system
PLoS ONE | www.plosone.org
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Figure 1. Body weight and left ventricular mass in IL-1R1-/- and IL-1Ra-/- mice. Genetically modified mice (both IL-1R1-/- and IL-1Ra-/- )
have significantly smaller body weights compared with the respective wild-type animals (WT). Left ventricular (LV) mass calculated at
echocardiography was not statistically different comparing IL-1R1-/- and IL-1Ra-/- and respectively WT, but the IL-1R1-/- had significantly greater LV
mass/weight ratio. N = 8–10 per group.
doi:10.1371/journal.pone.0027923.g001

cardioprotective effects of IL-1Ra in myocardial ischemia and
infarction [8,14], the current study shows for the first time that the
lack of endogenous IL-1Ra leads to more adverse remodeling.
Previous experiments showed that IL-1Ra transgenic mice, in
which IL-1Ra is overexpressed in fibroblasts, subjected to global
cardiac ischemia-reperfusion surgery simulating heart transplantation had a smaller extent of subendocardial infarct and reduced
apoptosis in cardiomyocytes [14]. Moreover, supplementation of
recombinant human IL-1Ra to the mouse lead to improved
cardiac remodeling after AMI [8].
These findings reinforce the concept that modulation of IL-1 is
a viable target for interventions aimed at preventing heart failure
after AMI, and, within the challenges and limitations of preclinical
and translational studies [15], they provide the frame to interpret
studies using pharmacologic IL-1 blockers in patients with AMI
[16]. With the exception of one study using a hamster anti-mouse
IL-1b antibody (not commercially available) which showed
adverse remodeling and increased cardiac rupture [17], all other
studies using either a recombinant human IL-1Ra [8], a
recombinant fusion protein binding circulation IL-1b and IL-1a
(IL-1Trap)[9], or a mouse engineered anti-IL-1b antibody
(XMA052 MG1K)[10], have shown a more favorable remodeling
associated with IL-1 blockade and no increase in the incidence of
cardiac rupture. All together, the data deriving from the
genetically manipulated mice and the more recent studies using
IL-1 blockers argue against the concept that IL-1b is necessary for
infarct healing.
During AMI, tissue injury leads to an intense sterile inflammation that is likely to be initially induced by toll-like receptor (TLR)
signaling by the many danger-associated molecular patterns
generated during cell death. TLR agonists induce a powerful
activation of nuclear factor k-B and induction of numerous
inflammatory mediators that recruit and activate leukocytes within
the injured myocardium. IL-1 is certainly among these soluble

Left ventricular enlargement and systolic dysfunction
AMI lead to LV enlargement and systolic dysfunction versus
sham operated mice (LVEDD, LVESD and LVEF–P,0.001).
When compared with the corresponding WT mice, IL-1R1-/mice had significantly less LV enlargement (measured as LVEDD
and LVESD) and less LV systolic dysfunction (measured as
LVEF)(Figure 2), whereas IL-1Ra-/- mice had worse LV
enlargement and dysfunction (Figure 3).

Indirect comparison between IL-1R1-/- and IL-1Ra-/- mice
When data from IL-1R1-/- and IL-1Ra-/- mice were
normalized to the WT, the WT mice displayed an intermediate
phenotype between the IL-1R1-/- mice–which were protected–
and the IL-1Ra-/- mice in which heart damage was exacerbated
(Figure 4).

Discussion
IL-1 is considered a key inflammatory mediator in the response
to sterile inflammation such as acute myocardial infarction. By
using 2 genetically modified mouse strains, the current study shows
that the lack of IL-1R1 signaling or the unopposed IL-1R1
signaling (due to lack of the IL-1Ra) is sufficient to modulate the
natural course of post-AMI cardiac remodeling.
In this mouse model of severe ischemic cardiomyopathy, the
lack of signaling through the IL-1R1 signaling post-AMI is
associated with a more favorable remodeling. This is an agreement
with a prior study showing more favorable remodeling following
myocardial ischemia-reperfusion injury due to transient coronary
occlusion [13].
The results of these experiments also show that endogenous IL1Ra plays a protective role in the myocardium during AMI by
preventing cell death and ensuing adverse cardiac remodeling.
While the data presented are in accordance with the proposed
PLoS ONE | www.plosone.org
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Figure 2. Infarct size, apoptosis and left ventricular remodeling in wild-type and IL-1R1-/- mice. When compared with the corresponding
wild-type mice, infarct scar size (Masson’s trichrome stain) and cardiomyocyte apoptotic rate (in-situ end labelling of DNA fragmentation–TUNEL)
were significantly smaller in IL-1R1-/- mice. Moreover, IL-1R1-/- mice had less left ventricular enlargement and systolic dysfunction 1 week after AMI.
N = 6–8 per group.
doi:10.1371/journal.pone.0027923.g002

involvement) has been linked to the genetic deficiency of the IL1Ra (DIRA), and has been found to be responsive to exogenous
IL-1Ra [19]. The DIRA syndrome, in which endogenous IL-1Ra
is lacking, is similar to syndromes of enhanced IL-1b production
due to genetic alterations of the cryopyrin gene (Cryopyrinassociated periodic syndromes [CAPS]), which are also responsive
to exogenous IL-1Ra [20], thus confirming the key role of IL-1/
IL-1Ra balance in disease activity.
One major limitation of the current study is that the IL-1R1-/and IL-1Ra-/- strains were generated in 2 different mouse lines
and hence a direct comparison between the 2 mutants cannot be
performed. Indeed, mouse strain may determine significant

mediators that greatly amplifies the inflammatory response in a
paracrine and autocrine fashion (‘‘IL-1 induces IL-1’’)[18].
Pharmacologic IL-1 blockade (or genetic deletion of the IL-1R1)
does not impede TLR signaling allowing for the initial
inflammatory response to injury, but may limit the occurrence
of additional tissue injury induced by IL-1. Cardiomyocytes in the
border zones of the AMI synthesize IL-1Ra to protect themselves
from IL-1 mediated injury. Mice lacking IL-1Ra lack this
endogenous protective mechanism and hence their cardiomyocytes (and other cell types) are at higher risk of death. A clinical
syndrome in children characterized by life-threatening systemic
inflammation (with particular involvement of skin and bone
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Figure 3. Infarct size, apoptosis and left ventricular remodeling in wild-type and IL-1Ra-/- mice. When compared with the corresponding
wild-type mice, infarct scar size (Masson’s trichrome stain) and cardiomyocyte apoptotic rate (in-situ end labelling of DNA fragmentation–TUNEL)
were significantly greater in IL-1Ra-/- mice. Moreover, IL-1Ra-/- mice had less left ventricular enlargement and systolic dysfunction 1 week after AMI.
N = 6–8 per group.
doi:10.1371/journal.pone.0027923.g003

Finally, no data on right ventricular dimensions, function or
pathology was recorded. Defining whether IL-1 is involved in
biventricular remodeling [22–23] could have further improved our
understanding of heart failure.
The mechanisms by which IL-1 signaling at the IL-1R1 level
drives adverse cardiac remodeling is not completely clear and have
not been explored in the current study. In vitro, IL-1 signaling
modulates cardiomyocyte survival independent of the function of
leukocytes [8,24]. IL-1 upregulates caspase-1 activity which has
been shown to promote cell death in cardiomyocytes [24–27]. In
vitro, IL-1Ra has been shown to promote cell survival and to
inhibit caspase-1 and caspase-9 [8]. Whether IL-1Ra promotes cell
survival in ways other than competing with IL-1b at the IL-1R1
levels is unknown, and requires further studies.

differences in the outcome of wound healing after myocardial
infarction [21]. With the use of indirect comparison after
normalization to the respective wild-type mouse, we could show
that a gradient of severity was present going from the IL-1R1-/mice through the WT and to the IL-1Ra-/- mice. Moreover, the
WT used in each study were not littermates because not
commercially available.
The relatively small number of mice studies makes it unable to
have reliable data on survival and on cardiac rupture. We noticed
a small increase in cardiac rupture in IL-1Ra-/- mice but it did not
reach statistical significance. Moreover, the lack of data regarding
leukocyte density and activation and MMP activation does not
allow us to determine whether enhanced MMP activation in IL1Ra-/- is the cause of cardiac rupture.
PLoS ONE | www.plosone.org
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Figure 4. Indirect comparison between the IL-1R1-/- and the IL-1Ra-/-. Considering that IL-1R1-/- and the IL-1Ra-/- mice were generated in
different backgrounds, a direct comparison between the 2 strains cannot be made. The Figure shows an indirect comparison between the 2 strains in
which the value of each strain is normalized to the corresponding wild-type mouse. In the comparison, the IL-1R1-/- mouse shows to have smaller
infarcts, less apoptosis and more favorable remodeling, wheras the IL-1Ra-/- mouse shows large infarcts, more apoptosis, and more unfavorable
remodeling.
doi:10.1371/journal.pone.0027923.g004

We chose the model of non-reperfused AMI because although
most of the patients with AMI receive some form of intervention
aimed at obtaining reperfusion, presently many patients achieve
incomplete tissue level reperfusion (no reflow), which negates the
benefit of reperfusion and is associated with an even greater risk of
subsequent heart failure [28–29].
In conclusion, modification of IL-1 signaling determining an
imbalance between IL-1 and IL-1Ra at the IL-1R1 level
determines the severity of cardiac remodeling after AMI in the

mouse, with reduced IL-1R1 signaling providing protection and
unopposed IL-1R1 signaling providing harm.
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